Claims
- 1. An antibacterial composition comprising a combination of a carbapenem having the following structure: ##STR112## wherein R is hydrogen or methyl, and
- R' is ##STR113## wherein M is CH.sub.3 or H;
- and the easily removable pharmaceutically acceptable salt or ester derivatives thereof; and a dipeptidase (E.C.3.4.13.11) inhibitor, of the following structure, ##STR114## wherein R.sup.2 and R.sup.3 are hydrocarbon radicals in the range respectively of 3-10 and 1-15 carbon atoms; in either of these hydrocarbon radicals R.sup.2 and R.sup.3, up to 6 hydrogens may be replaced by halogens, or a non-terminal methylene may be replaced by oxygen or sulphur, including oxidized forms of the latter; a terminal hydrogen in R.sup.3 can also be replaced by a hydroxyl or thiol group, which may be acylated, such as with an alkanoyl acid of 1-8 carbon atoms, or carbamoylated, including alkyl and dialkyl carbamate derivatives; or the hydrogen can be replaced by an amino group, which may be derivatized as in an acylamino, ureido, amidino, guanidino, or alkyl or substituted alkyl amino group, including quaternary nitrogen groupings; or, alternatively, there may be replacement by acid groups such as carboxylic, phosphonic or sulfonic acid groups or esters or amides thereof, as well as cyano; or combinations thereof, such as a terminal amino acid grouping; the ratio of the carbapenem to the dipeptidase inhibitor being within in the range of about 1:3 to 30:1.
- 2. The composition of claim 1 in which the combination is mixed with a pharmaceutical carrier.
- 3. The composition of claim 2 in which the carrier is adapted for injection.
- 4. The composition of claim 1 in which the carbapenem is 2-(1-acetimidoyl-pyrollidin-3-yl-thio)-6-(1-hydroxyethyl)-carbapen-2-em-3-carboxylic acid or sodium carboxylate.
- 5. The composition of claim 4 wherein the dipeptidase inhibitor is Z-7-(L-amino-carboxyethylthio)-2-(2,2-dimethylcyclopropane carboxamido)-2-heptanoic acid.
CROSS REFERENCE TO RELATED APPLICATIONS
This is a continuation of application Ser. No. 07/471,678, filed Jan. 25, 1990, now abandoned, which is a continuation of application Ser. No. 07/384,845, filed July 24, 1989, now abandoned, which is a continuation of application Ser. No. 06/880,339, filed June 25, 1986, now abandoned, which is a continuation of application Ser. No. 06/605,343, filed Apr. 30, 1984, now abandoned, which is a continuation-in-part of application Ser. No. 06/340,152, filed Jan. 18, 1982, now abandoned, which is a continuation-in-part of application Ser. No. 06/291,711, filed Aug. 10, 1981, now U.S. Pat. No. 4,539,208, which is a continuation-in-part of application Ser. No. 06/187,929, filed Sept. 17, 1980, now abandoned, which is a continuation-in-part of application Ser. No. 06/050,232 filed June 22, 1979, now abandoned, which is a continuation-in-part of application Ser. No. 05/927,213, filed July 24, 1978, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4539208 |
Kahan et al. |
Sep 1985 |
|
4552873 |
Miyadera et al. |
Nov 1985 |
|
Foreign Referenced Citations (4)
Number |
Date |
Country |
0007614 |
Feb 1979 |
EPX |
0028778 |
May 1981 |
EPX |
2013674 |
Aug 1979 |
GBX |
2042520 |
Sep 1980 |
GBX |
Non-Patent Literature Citations (2)
Entry |
Journal of Antibiotics, vol. 36, No. 8, Aug. (1983) pp. 1034-1039. |
Drugs of the Future, vol. 10, No. 12 (1985) pp. 989-992. |
Continuations (4)
|
Number |
Date |
Country |
Parent |
471678 |
Jan 1990 |
|
Parent |
384845 |
Jul 1989 |
|
Parent |
880339 |
Jun 1986 |
|
Parent |
605343 |
Apr 1984 |
|
Continuation in Parts (5)
|
Number |
Date |
Country |
Parent |
340152 |
Jan 1982 |
|
Parent |
291711 |
Aug 1981 |
|
Parent |
187929 |
Sep 1980 |
|
Parent |
50232 |
Jun 1979 |
|
Parent |
927213 |
Jul 1978 |
|